Eli Lilly’s stock soars 7% after beating expectations with a bullish 2026 revenue forecast, fueled by explosive demand for its GLP-1 drugs—especially after FDA approval of the oral version of its blockbuster weight-loss med. With clinical data already promising for its next-gen retatrutide drug set for Q1 2025 FDA submission, investors are betting big: shares have surged 40% since April and are up 3% year-to-date as the pharma giant dominates the weight-loss revolution.
Listen in comfort: Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn.
Advertise on DNN: advertise@thednn.ai
This is an automated, high-level news summary based on public reporting. Report issues to feedback@thednn.ai.
Podden och tillhörande omslagsbild på den här sidan tillhör
The Daily News Now!. Innehållet i podden är skapat av The Daily News Now! och inte av,
eller tillsammans med, Poddtoppen.
